drugset / Trial / NCT01091896

Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage

NCT01091896 ↗

Phase 2 Unknown 1 enrolled University of Sao Paulo
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to determine the effect of pre and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to vitrectomy without bevacizumab injection.

Timeline

Start
2010-01
Primary completion
2010-09
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Intravitreal